Eligible Medicare Part D members can get Wegovy, Zepbound KwikPen or Foundayo for a flat $50 monthly copay from July 1, 2026 through December 31, 2027 (BMI 35+, or 27+ with a qualifying condition). If you qualify, use it. If you do not, the cash-pay routes are below.
By Dr. SkinnyVIP · Published October 19, 2026 · Quotes link to the original policy or report
“Beneficiaries may be able to get a GLP-1 prescription for weight loss for $50 a month.”
“the pill and injectable formulations of Wegovy, the KwikPen formulation of Zepbound, and the Foundayo pill.”
“It will run from July 1, 2026, through Dec. 31, 2027.”
CMS's own announcement is at cms.gov. If you are on Medicare and meet the criteria below, this is the best-priced route to a brand-name GLP-1 that exists today, and we would rather you use it than pay us.
“you must be enrolled in a Medicare Part D plan, which covers prescription drugs.”
“they have a body mass index of 27 or higher and have a condition such as heart disease or prediabetes, among others.”
“People with BMIs of 35 or higher automatically qualify.”
After approval, NPR reports patients pay the flat $50 copayment at the pharmacy. Ask your prescriber to start the request; your Part D plan handles the rest.
Three groups fall outside the Bridge: people not on Medicare Part D, people with a BMI between 27 and 34.9 without a listed qualifying condition, and people who want a formulation the program does not cover (for example Zepbound vials). For them, the published routes are LillyDirect's self-pay Zepbound prices ($299 to $699 a month by dose, per our index) or clinician-prescribed compounded tirzepatide.
SkinnyVIP's compounded tirzepatide is $695 for a 3-month plan (about $232 a month) or $350 for a single month, the same at every dose, with no membership and nothing that renews. Compounded medications are not FDA-approved products; a licensed clinician reviews every request and prescription is not guaranteed. Read how it works.
A flat $50 monthly copay at the pharmacy for Wegovy (pill or injection), Zepbound KwikPen or Foundayo, per NPR's reporting on the CMS program. It runs July 1, 2026 through December 31, 2027.
Medicare Part D members with a BMI of 35 or higher, or a BMI of 27 or higher plus a qualifying condition such as heart disease or prediabetes, per NPR.
No. It covers the FDA-approved brand products listed. Compounded tirzepatide is a separate, cash-pay product that is not FDA-approved.
LillyDirect's self-pay Zepbound prices, your employer plan if it still covers GLP-1s, or clinician-prescribed compounded tirzepatide. SkinnyVIP's is $695 for 3 months or $350 for one month, any dose, with no membership or renewal.
Ask your plan about exceptions, check the brand-name cash routes, then compare. SkinnyVIP: $695 for 3 months (about $232/month) or $350 for one, any dose, nothing renews.
Start your consultationCompounded tirzepatide is prepared by licensed compounding pharmacies under physician supervision. Compounded medications are not FDA-approved products, and FDA does not review compounded drugs for safety, effectiveness, or quality before marketing. Compounded tirzepatide is separate from FDA-approved Mounjaro® and Zepbound®. A licensed clinician reviews every request; prescription is not guaranteed. Individual results vary. Not affiliated with Novo Nordisk (Ozempic®/Wegovy®) or Eli Lilly (Mounjaro®/Zepbound®). This page is general information about published coverage policies, not insurance, legal or medical advice; confirm details with your plan.